A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Latest Information Update: 22 Jun 2024
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Nirogacestat (Primary) ; Pomalidomide (Primary) ; Teclistamab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MajesTEC-2
- Sponsors Janssen Research & Development
- 30 Jan 2024 Planned primary completion date changed from 28 Jun 2024 to 31 Oct 2024.
- 10 Oct 2023 Planned End Date changed from 28 Jun 2024 to 24 Feb 2025.
- 15 Jun 2023 Preliminary safety (primary objective), efficacy, and PK data presented at the 28th Congress of the European Haematology Association.